Business Information
The company's principal activities are to develop a series of proprietary immune regulating hormones (irhs) for the treatment of immune system and metabolic disorders. The purpose of irh therapy is to direct, through controlling gene expression, the production of key cytokines and enzymes that re-regulate immune and metabolic functions toward homeostasis, a profile that could be useful in a wide variety of diseases. The company has a number of investigational irhs under development, including neumune (he2100), which the company is co-developing with the U.S. Military for use in protecting the body's bone marrow from acute radiation injury and immunitin (he2000), which is infectious disease compound, is currently being studied in a number of infectious diseases. Additionally, the company is also developing irhs for protection from chemotherapy and other conditions of immune dysregulation. On 25-Feb-2004, the company acquired congressional pharmaceutical corporation.
|
|
Name |
Title
|
Email
|
| Richard Hollis | Founder, Chmn., CEO | N/A | | James Frincke | Chief Scientific Officer | N/A | | Robert Weber | VP, Controller, Chief Accounting Officer | N/A | | Scott Freeman | Chief Medical Officer | N/A | | Christopher Reading | Exec. VP - Scientific Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 444 | (30,231) | | 2005 | 56 | (29,441) | | 2004 | 63 | (24,757)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
